{"id":"aclacinomycin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL498884","moleculeType":"Small molecule","molecularWeight":"809.86"},"aliases":["ACM"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"72 kDa type IV collagenase, DNA topoisomerase II, 5-hydroxytryptamine receptor 2B"},"_scrapedAt":"2026-03-28T00:58:56.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:44:45.523994+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Acute myeloid leukemia, disease","diseaseId":"acute-myeloid-leukemia-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT05662956","phase":"PHASE2","title":"A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients","status":"COMPLETED","sponsor":"Hematology department of the 920th hospital","startDate":"2022-12-01","conditions":"Acute Myeloid Leukemia","enrollment":114},{"nctId":"NCT05726110","phase":"PHASE3","title":"Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2023-01-29","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT06301425","phase":"NA","title":"MRD Response-adapted Allo-HSCT for Adverse-risk AML","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-05-24","conditions":"Acute Myeloid Leukemia","enrollment":178},{"nctId":"NCT06084819","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2023-08-01","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT05805072","phase":"NA","title":"Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-05-01","conditions":"Relapsed/Refractory AML","enrollment":20},{"nctId":"NCT05807347","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Hematology department of the 920th hospital","startDate":"2023-02-01","conditions":"Refractory/Relapse Acute Myeloid Leukemia","enrollment":42},{"nctId":"NCT03173612","phase":"NA","title":"The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":132},{"nctId":"NCT02723448","phase":"PHASE1","title":"Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-12-05","conditions":"Vasculopathy, Retinal, With Cerebral Leukodystrophy, Cerebroretinal Vasculopathy, Hereditary","enrollment":4},{"nctId":"NCT03181815","phase":"PHASE2","title":"Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01-01","conditions":"Acute Myeloid Leukemia, Relapse Leukemia","enrollment":48},{"nctId":"NCT02662647","phase":"PHASE2","title":"Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2015-04","conditions":"AML","enrollment":30},{"nctId":"NCT03642236","phase":"PHASE2, PHASE3","title":"Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-08","conditions":"FLT3-ITD Mutation, Acute Myeloid Leukemia, Brutons Tyrosine Kinase","enrollment":122},{"nctId":"NCT02850822","phase":"","title":"Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-07","conditions":"Myelodysplastic Syndrome, Chemotherapy","enrollment":250},{"nctId":"NCT03026842","phase":"PHASE4","title":"Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-01","conditions":"Acute Myeloid Leukemia","enrollment":180},{"nctId":"NCT02432911","phase":"NA","title":"Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old","status":"UNKNOWN","sponsor":"Jianxiang Wang","startDate":"2015-04","conditions":"Acute Myeloid Leukemia","enrollment":300},{"nctId":"NCT02432872","phase":"NA","title":"Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years","status":"UNKNOWN","sponsor":"Jianxiang Wang","startDate":"2015-04","conditions":"Acute Myeloid Leukemia","enrollment":300},{"nctId":"NCT01690507","phase":"PHASE1, PHASE2","title":"Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2012-11","conditions":"MDS, AML","enrollment":29}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"BONE MARROW FAILURE"},{"count":5,"reaction":"DRUG-INDUCED LIVER INJURY"},{"count":5,"reaction":"HAEMATOTOXICITY"},{"count":5,"reaction":"INFECTION"},{"count":4,"reaction":"DRUG INEFFECTIVE"},{"count":3,"reaction":"NAUSEA"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"BLAST CRISIS IN MYELOGENOUS LEUKAEMIA"},{"count":2,"reaction":"LUNG INFECTION"},{"count":2,"reaction":"OFF LABEL USE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"aclacinomycin","genericName":"aclacinomycin","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:44:45.523994+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}